Deubiquitinases and the new therapeutic opportunities offered to cancer

Endocrine-Related Cancer

Volumn 22, Issue 1, 2015, Pages T35-T54

  Pfoh, Roland ^a   Lacdao, Ira Kay ^a   Saridakis, Vivian ^a  

^a YORK UNIVERSITY   (Canada)

Author keywords

A20; Ataxin 3; BAP1; CYLD; Deubiquitinases; UCHL1; USP22; USP7

Indexed keywords

A20 ENZYME; ATAXIN 3; BETULIC ACID; BORTEZOMIB; BRCA1 ASSOCIATED RING DOMAIN PROTEIN 1; CARFILZOMIB; CISPLATIN; CYLD ENZYME; DEUBIQUITINASE; TAMOXIFEN; UBIQUITIN SPECIFIC PROTEASE 22; UBIQUITIN SPECIFIC PROTEASE 7; UCHL1 ENZYME; UNCLASSIFIED DRUG; UBIQUITIN; UBIQUITIN PROTEIN LIGASE; UBIQUITIN THIOLESTERASE;

ADRENAL CORTEX CARCINOMA; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER THERAPY; CARCINOGENESIS; DRUG TARGETING; ENDOCRINE TUMOR; ENZYME STRUCTURE; HUMAN; OVARY CANCER; PHEOCHROMOCYTOMA; PROTEIN INTERACTION; REGULATORY MECHANISM; REVIEW; THYROID CANCER; UBIQUITINATION; ANIMAL; ANTAGONISTS AND INHIBITORS; ENZYMOLOGY; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS; SIGNAL TRANSDUCTION;

ANIMALS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; SIGNAL TRANSDUCTION; UBIQUITIN; UBIQUITIN THIOLESTERASE; UBIQUITIN-PROTEIN LIGASES; UBIQUITIN-SPECIFIC PROTEASES;

EID: 84923585238     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-14-0516     Document Type: Review

References (218)

1. Alimonti A, Carracedo A, Clohessy JG, Trotman LC, Nardella C, Egia A, Salmena L, Sampieri K, Haveman WJ, Brogi E et al. 2010 Subtle variations in Pten dose determine cancer susceptibility. Nature Genetics 42 454-458. (doi:10.1038/ng.556)
2. Allende-Vega N, Sparks A, Lane DP & Saville MK 2010 MdmX is a substrate for the deubiquitinating enzyme USP2a. Oncogene 29 432-441. (doi:10.1038/onc.2009.330)
3. Amerik AY & Hochstrasser M 2004 Mechanism and function of deubiquitinating enzymes. Biochimica et Biophysica Acta 1695 189-207. (doi:10.1016/j.bbamcr.2004.10.003)
4. Aravind L & Koonin EV 2000 The U box is a modified RING finger - a common domain in ubiquitination. Current Biology 10 R132-R134. (doi:10.1016/S0960-9822(00)00398-5)
5. Avvakumov GV, Walker JR, Xue S, Finerty PJ Jr, Mackenzie F, Newman EM & Dhe-Paganon S 2006 Amino-terminal dimerization, NRDP1-rhodanese interaction, and inhibited catalytic domain conformation of the ubiquitin-specific protease 8 (USP8). Journal of Biological Chemistry 281 38061-38070. (doi:10.1074/jbc.M606704200)
6. Becker K, Marchenko ND, Palacios G & Moll UM 2008 A role of HAUSP in tumor suppression in a human colon carcinoma xenograft model. Cell Cycle 7 1205-1213. (doi:10.4161/cc.7.9.5756)
7. Ben-Aroya S, Agmon N, Yuen K, Kwok T, McManus K, Kupiec M & Hieter P 2010 Proteasome nuclear activity affects chromosome stability by controlling the turnover of Mms22, a protein important for DNA repair. PLoS Genetics 6 e1000852. (doi:10.1371/journal.pgen.1000852)
8. Benassi B, Flavin R, Marchionni L, Zanata S, Pan Y, Chowdhury D, Marani M, Strano S, Muti P, Blandino G et al. 2012 MYC is activated by USP2a-mediated modulation of microRNAs in prostate cancer. Cancer Discovery 2 236-247. (doi:10.1158/2159-8290.CD-11-0219)
9. Bhattacharya S & Ghosh MK 2014a Cell death and deubiquitinases: perspectives in cancer. BioMed Research International 2014 435197. (doi:10.1155/2014/435197)
10. Bhattacharya S & Ghosh MK 2014b HAUSP, a novel deubiquitinase for Rb - MDM2 the critical regulator. FEBS Journal 281 3061-3078. (doi:10.1111/febs.12843)
11. de Bie P, Zaaroor-Regev D & Ciechanover A 2010 Regulation of the polycomb protein RING1B ubiquitination by USP7. Biochemical and Biophysical Research Communications 400 389-395. (doi:10.1016/j.bbrc.2010.08.082)
12. Bold R 2004 "Development of the proteasome inhibitor Velcade (Bortezomib)" by Julian Adams, Ph.D., and Michael Kauffman, M.D., Ph.D. Cancer Investigation 22 328-329. (doi:10.1081/CNV-120030223)
13. Bosanac I, Wertz IE, Pan B, Yu C, Kusam S, Lam C, Phu L, Phung Q, Maurer B, Arnott D et al. 2010 Ubiquitin binding to A20 ZnF4 is required for modulation of NF-κB signaling. Molecular Cell 40 548-557. (doi:10.1016/j.molcel.2010.10.009)
14. Boudreaux DA, Maiti TK, Davies CW & Das C 2010 Ubiquitin vinyl methyl ester binding orients the misaligned active site of the ubiquitin hydrolase UCHL1 into productive conformation. PNAS 107 9117-9122. (doi:10.1073/pnas.0910870107)
15. Brait M, Maldonado L, Noordhuis MG, Begum S, Loyo M, Poeta ML, Barbosa A, Fazio VM, Angioli R, Rabitti C et al. 2013 Association of promoter methylation of VGF and PGP9.5 with ovarian cancer progression. PLoS ONE 8 e70878. (doi:10.1371/journal.pone.0070878)
16. Brummelkamp TR, Nijman SM, Dirac AM & Bernards R 2003 Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-κB. Nature 424 797-801. (doi:10.1038/nature01811)
17. Burnett B, Li F & Pittman RN 2003 The polyglutamine neurodegenerative protein ataxin-3 binds polyubiquitylated proteins and has ubiquitin protease activity. Human Molecular Genetics 12 3195-3205. (doi:10.1093/hmg/ddg344)
18. Burska UL, Harle VJ, Coffey K, Darby S, Ramsey H, O'Neill D, Logan IR, Gaughan L & Robson CN 2013 Deubiquitinating enzyme Usp12 is a novel co-activator of the androgen receptor. Journal of Biological Chemistry 288 32641-32650. (doi:10.1074/jbc.M113.485912)
19. Butler LR, Densham RM, Jia J, Garvin AJ, Stone HR, Shah V, Weekes D, Festy F, Beesley J & Morris JR 2012 The proteasomal de-ubiquitinating enzyme POH1 promotes the double-strand DNA break response. EMBO Journal 31 3918-3934. (doi:10.1038/emboj.2012.232)
20. Carneiro AP, Reis CF, Morari EC, Maia YC, Nascimento R, Bonatto JM, de Souza MA, Goulart LR & Ward LS 2014 A putative OTU domain-containing protein 1 deubiquitinating enzyme is differentially expressed in thyroid cancer and identifies less-aggressive tumours. British Journal of Cancer 111 551-558. (doi:10.1038/bjc.2014.331)
21. Chan JK & Greene WC 2011 NF-κB/Rel: agonist and antagonist roles in HIV-1 latency. Current Opinion in HIV and AIDS 6 12-18. (doi:10.1097/COH.0b013e32834124fd)
22. Chanudet E, Ye H, Ferry J, Bacon CM, Adam P, Muller-Hermelink HK, Radford J, Pileri SA, Ichimura K, Collins VP et al. 2009 A20 deletion is associated with copy number gain at the TNFA/B/C locus and occurs preferentially in translocation-negative MALT lymphoma of the ocular adnexa and salivary glands. Journal of Pathology 217 420-430. (doi:10.1002/path.2466)
23. Chauhan D, Tian Z, Nicholson B, Kumar KG, Zhou B, Carrasco R, McDermott JL, Leach CA, Fulcinniti M, Kodrasov MP et al. 2012 A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance. Cancer Cell 22 345-358. (doi:10.1016/j.ccr.2012.08.007)
24. Chen ZJ 2005 Ubiquitin signalling in the NF-κB pathway. Nature Cell Biology 7 758-765. (doi:10.1038/ncb0805-758)
25. Ching W, Koyuncu E, Singh S, Arbelo-Roman C, Hartl B, Kremmer E, Speiseder T, Meier C & Dobner T 2013 A ubiquitin-specific protease possesses a decisive role for adenovirus replication and oncogene-mediated transformation. PLoS Pathogens 9 e1003273. (doi:10.1371/journal.ppat.1003273)
26. Chintharlapalli S, Papineni S, Ramaiah SK & Safe S 2007 Betulinic acid inhibits prostate cancer growth through inhibition of specificity protein transcription factors. Cancer Research 67 2816-2823. (doi:10.1158/0008-5472.CAN-06-3735)
27. Chu IM, Hengst L & Slingerland JM 2008 The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nature Reviews. Cancer 8 253-267. (doi:10.1038/nrc2347)
28. Ciechanover A 2003 The ubiquitin proteolytic system and pathogenesis of human diseases: a novel platform for mechanism-based drug targeting. Biochemical Society Transactions 31 474-481. (doi:10.1042/BST0310474)
29. Ciechanover A 2006 The ubiquitin proteolytic system: from an idea to the patient bed. Proceedings of the American Thoracic Society 3 21-31. (doi:10.1513/pats.200510-106JH)
30. Ciechanover A & Schwartz AL 2004 The ubiquitin system: pathogenesis of human diseases and drug targeting. Biochimica et Biophysica Acta 1695 3-17. (doi:10.1016/j.bbamcr.2004.09.018)
31. Ciechanover A, Orian A & Schwartz AL 2000 Ubiquitin-mediated proteolysis: biological regulation via destruction. BioEssays: News and Reviews in Molecular, Cellular and Developmental Biology 22 442-451. (doi:10.1002/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO;2-Q)
32. Clague MJ, Barsukov I, Coulson JM, Liu H, Rigden DJ & Urbe S 2013 Deubiquitylases from genes to organism. Physiological Reviews 93 1289-1315. (doi:10.1152/physrev.00002.2013)
33. Cochrane DR, Bernales S, Jacobsen BM, Cittelly DM, Howe EN, D'Amato NC, Spoelstra NS, Edgerton SM, Jean A, Guerrero J et al. 2014 Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide. Breast Cancer Research 16 R7. (doi:10.1186/bcr3599)
34. Colland F, Formstecher E, Jacq X, Reverdy C, Planquette C, Conrath S, Trouplin V, Bianchi J, Aushev VN, Camonis J et al. 2009 Small-molecule inhibitor of USP7/HAUSP ubiquitin protease stabilizes and activates p53 in cells. Molecular Cancer Therapeutics 8 2286-2295. (doi:10.1158/1535-7163.MCT-09-0097)
35. Cooper EM, Cutcliffe C, Kristiansen TZ, Pandey A, Pickart CM & Cohen RE 2009 K63-specific deubiquitination by two JAMM/MPNC complexes: BRISC-associated Brcc36 and proteasomal Poh1. EMBO Journal 28 621-631. (doi:10.1038/emboj.2009.27)
36. Curcio-Morelli C, Zavacki AM, Christofollete M, Gereben B, de Freitas BC, Harney JW, Li Z, Wu G & Bianco AC 2003 Deubiquitination of type 2 iodothyronine deiodinase by von Hippel-Lindau protein-interacting deubiquitinating enzymes regulates thyroid hormone activation. Journal of Clinical Investigation 112 189-196. (doi:10.1172/JCI18348)
37. Dai W, Yao Y, Zhou Q & Sun CF 2014 Ubiquitin-specific peptidase 22, a histone deubiquitinating enzyme, is a novel poor prognostic factor for salivary adenoid cystic carcinoma. PLoS ONE 9 e87148. (doi:10.1371/journal.pone.0087148)
38. D'Arcy P & Linder S 2012 Proteasome deubiquitinases as novel targets for cancer therapy. International Journal of Biochemistry & Cell Biology 44 1729-1738. (doi:10.1016/j.biocel.2012.07.011)
39. Das C, Hoang QQ, Kreinbring CA, Luchansky SJ, Meray RK, Ray SS, Lansbury PT, Ringe D & Petsko GA 2006 Structural basis for conformational plasticity of the Parkinson's disease-associated ubiquitin hydrolase UCH-L1. PNAS 103 4675-4680. (doi:10.1073/pnas. 0510403103)
40. Davies CW, Chaney J, Korbel G, Ringe D, Petsko GA, Ploegh H & Das C 2012 The co-crystal structure of ubiquitin carboxy-terminal hydrolase L1 (UCHL1) with a tripeptide fluoromethyl ketone (Z-VAE(OMe)-FMK). Bioorganic & Medicinal Chemistry Letters 22 3900-3904. (doi:10.1016/j.bmcl.2012.04.124)
41. Dean JL & Knudsen KE 2013 The role of tumor suppressor dysregulation in prostate cancer progression. Current Drug Targets 14 460-471. (doi:10.2174/1389450111314040007)
42. Dentice M, Bandyopadhyay A, Gereben B, Callebaut I, Christoffolete MA, Kim BW, Nissim S, Mornon JP, Zavacki AM, Zeold A et al. 2005 The Hedgehog-inducible ubiquitin ligase subunit WSB-1 modulates thyroid hormone activation and PTHrP secretion in the developing growth plate. Nature Cell Biology 7 698-705. (doi:10.1038/ncb1272)
43. Dirac AM & Bernards R 2010 The deubiquitinating enzyme USP26 is a regulator of androgen receptor signaling. Molecular Cancer Research 8 844-854. (doi:10.1158/1541-7786.MCR-09-0424)
44. Draker R, Sarcinella E & Cheung P 2011 USP10 deubiquitylates the histone variant H2A.Z and both are required for androgen receptor-mediated gene activation. Nucleic Acids Research 39 3529-3542. (doi:10.1093/nar/gkq1352)
45. Du Z, Song J, Wang Y, Zhao Y, Guda K, Yang S, Kao HY, Xu Y, Willis J, Markowitz SD et al. 2010 DNMT1 stability is regulated by proteins coordinating deubiquitination and acetylation-driven ubiquitination. Science Signaling 3 ra80. (doi:10.1126/scisignal.2001462)
46. Du M, Yuan T, Schilter KF, Dittmar RL, Mackinnon A, Huang X, Tschannen M, Worthey E, Jacob H, Xia S et al. 2015 Prostate cancer risk locus at 8q24 as a regulatory hubbyphysical interactions with multiple genomicloci across the genome. Human Molecular Genetics 24 154-166. (doi:10.1093/hmg/ddu426)
47. Eichhorn PJ, Rodon L, Gonzalez-Junca A, Dirac A, Gili M, Martinez-Saez E, Aura C, Barba I, Peg V, Prat A et al. 2012 USP15 stabilizes TGF-β receptor I and promotes oncogenesis through the activation of TGF-β signaling in glioblastoma. Nature Medicine 18 429-435. (doi:10.1038/nm.2619)
48. Espinosa-de-Los-Monteros-Franco VA, Martinez-Madrigal F & Ortiz-Hidalgo C 2009 Granular cell tumor (Abrikossoff tumor) of the thyroid gland. Annals of Diagnostic Pathology 13 269-271. (doi:10.1016/j.anndiagpath.2008.04.008)
49. Evert BO, Araujo J, Vieira-Saecker AM, de Vos RA, Harendza S, Klockgether T & Wullner U 2006 Ataxin-3 represses transcription via chromatin binding, interaction with histone deacetylase 3, and histone deacetylation. Journal of Neuroscience 26 11474-11486. (doi:10.1523/JNEUROSCI.2053-06.2006)
50. Faesen AC, Dirac AM, Shanmugham A, Ovaa H, Perrakis A & Sixma TK 2011 Mechanism of USP7/HAUSP activation by its C-terminal ubiquitin-like domain and allosteric regulation by GMP-synthetase. Molecular Cell 44 147-159. (doi:10.1016/j.molcel.2011.06.034)
51. Fan YH, Cheng J, Vasudevan SA, Dou J, Zhang H, Patel RH, Ma IT, Rojas Y, Zhao Y, Yu Y et al. 2013 USP7 inhibitor P22077 inhibits neuroblastoma growth via inducing p53-mediated apoptosis. Cell Death & Disease 4 e867. (doi:10.1038/cddis.2013.400)
52. Fang S & Weissman AM 2004 A field guide to ubiquitylation. Cellular and Molecular Life Sciences 61 1546-1561. (doi:10.1007/s00018-004-4129-5)
53. Faustrup H, Bekker-Jensen S, Bartek J, Lukas J & Mailand N 2009 USP7 counteracts SCFbTrCP - but not APCCdh1-mediated proteolysis of Claspin. Journal of Cell Biology 184 13-19. (doi:10.1083/jcb.200807137)
54. Fraile JM, Quesada V, Rodriguez D, Freije JM & Lopez-Otin C 2012 Deubiquitinases in cancer: new functions and therapeutic options. Oncogene 31 2373-2388. (doi:10.1038/onc.2011.443)
55. Fu X, Creighton CJ, Biswal NC, Kumar V, Shea M, Herrera S, Contreras A, Gutierrez C, Wang T, Nanda S et al. 2014 Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase. Breast Cancer Research 16 430. (doi:10.1186/s13058-014-0430-x)
56. Garolla A, Ferlin A, Vinanzi C, Roverato A, Sotti G, Artibani W & Foresta C 2005 Molecular analysis of the androgen receptor gene in testicular cancer. Endocrine-Related Cancer 12 645-655. (doi:10.1677/erc.1.00954)
57. Gereben B, Zavacki AM, Ribich S, Kim BW, Huang SA, Simonides WS, Zeold A & Bianco AC 2008 Cellular and molecular basis of deiodinase-regulated thyroid hormone signaling. Endocrine Reviews 29 898-938. (doi:10.1210/er.2008-0019)
58. Gheorgheosu D, Duicu O, Dehelean C, Soica C & Muntean D 2014 Betulinic acid as a potent and complex antitumor phytochemical: a minireview. Anti-Cancer Agents in Medicinal Chemistry 14 936-945. (doi:10.2174/1871520614666140223192148)
59. Giovinazzi S, Sirleto P, Aksenova V, Morozov VM, Zori R, Reinhold WC & Ishov AM 2014 Usp7 protects genomic stability by regulating Bub3. Oncotarget 5 3728-3742.
60. Glinsky GV 2005 Death-from-cancer signatures and stem cell contribution to metastatic cancer. Cell Cycle 4 1171-1175. (doi:10.4161/cc.4.9.2001)
61. Glinsky GV 2006 Genomic models of metastatic cancer: functional analysis of death-from-cancer signature genes reveals aneuploid, anoikis-resistant, metastasis-enabling phenotype with altered cell cycle control and activated polycomb group (PcG) protein chromatin silencing pathway. Cell Cycle 5 1208-1216. (doi:10.4161/cc.5.11.2796)
62. Glinsky GV, Berezovska O & Glinskii AB 2005 Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. Journal of Clinical Investigation 115 1503-1521. (doi:10.1172/JCI23412)
63. Graner E, Tang D, Rossi S, Baron A, Migita T, Weinstein LJ, Lechpammer M, Huesken D, Zimmermann J, Signoretti S et al. 2004 The isopeptidase USP2a regulates the stability of fatty acid synthase in prostate cancer. Cancer Cell 5 253-261. (doi:10.1016/S1535-6108(04)00055-8)
64. Gusella JF & MacDonald ME 2000 Molecular genetics: unmasking polyglutamine triggers in neurodegenerative disease. Nature Reviews. Neuroscience 1 109-115. (doi:10.1038/35039051)
65. Harhaj EW & Dixit VM 2012 Regulation of NF-κB by deubiquitinases. Immunological Reviews 246 107-124. (doi:10.1111/j.1600-065X.2012.01100.x)
66. Hayashi M, Jono H, Shinriki S, Nakamura T, Guo J, Sueta A, Tomiguchi M, Fujiwara S, Yamamoto-Ibusuki M, Murakami K et al. 2014 Clinical significance of CYLD downregulation in breast cancer. Breast Cancer Research and Treatment 143 447-457. (doi:10.1007/s10549-013-2824-3)
67. Heinlein CA & Chang C 2004 Androgen receptor in prostate cancer. Endocrine Reviews 25 276-308. (doi:10.1210/er.2002-0032)
68. Hibi K, Liu Q, Beaudry GA, Madden SL, Westra WH, Wehage SL, Yang SC, Heitmiller RF, Bertelsen AH, Sidransky D et al. 1998 Serial analysis of gene expression in non-small cell lung cancer. Cancer Research 58 5690-5694.
69. Hibi K, Westra WH, Borges M, Goodman S, Sidransky D & Jen J 1999 PGP9.5 as a candidate tumor marker for non-small-cell lung cancer. American Journal of Pathology 155 711-715. (doi:10.1016/S0002-9440(10)65169-3)
70. Hicke L 2001 Protein regulation by monoubiquitin. Nature Reviews. Molecular Cell Biology 2 195-201. (doi:10.1038/35056583)
71. Hochstrasser M 1996 Ubiquitin-dependent protein degradation. Annual Review of Genetics 30 405-439. (doi:10.1146/annurev.genet.30.1.405)
72. Hofmann K & Falquet L 2001 A ubiquitin-interacting motif conserved in components of the proteasomal and lysosomal protein degradation systems. Trends in Biochemical Sciences 26 347-350. (doi:10.1016/S0968-0004(01)01835-7)
73. Holland AJ & Cleveland DW 2012 The deubiquitinase USP44 is a tumor suppressor that protects against chromosome missegregation. Journal o Clinical Investigation 122 4325-4328. (doi:10.1172/JCI66420)
74. Holowaty MN, Zeghouf M, Wu H, Tellam J, Athanasopoulos V, Greenblatt & Frappier L 2003 Protein profiling with Epstein-Barr nuclear antigen-reveals an interaction with the herpesvirus-associated ubiquitin-specific protease HAUSP/USP7. Journal of Biological Chemistry 278 29987-29994. (doi:10.1074/jbc.M303977200)
75. van der Horst A, de Vries-Smits AM, Brenkman AB, van Triest MH, van den Broek N, Colland F, Maurice MM & Burgering BM 2006 FOXO4 transcriptional activity is regulated by monoubiquitination and USP7/HAUSP. Nature Cell Biology 8 1064-1073. (doi:10.1038/ncb1469)
76. Howell VM, Gill A, Clarkson A, Nelson AE, Dunne R, Delbridge LW, Robinson BG, Teh BT, Gimm O & Marsh DJ 2009 Accuracy of combine protein gene product 9.5 and parafibromin markers for immuno-histochemical diagnosis of parathyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 94 434-441. (doi:10.1210/jc.2008-1740)
77. Hu M, Li P, Li M, Li W, Yao T, Wu JW, Gu W, Cohen RE & Shi Y 2002 Crysta structure of a UBP-family deubiquitinating enzyme in isolation and i complex with ubiquitin aldehyde. Cell 111 1041-1054. (doi:10.1016/S0092-8674(02)01199-6)
78. Hu M, Li P, Song L, Jeffrey PD, Chenova TA, Wilkinson KD, Cohen RE & Shi Y 2005 Structure and mechanisms of the proteasome-associated deubiquitinating enzyme USP14. EMBO Journal 24 3747-3756. (doi:10.1038/sj.emboj.7600832)
79. Hymowitz SG & Wertz IE 2010 A20: from ubiquitin editing to tumour suppression. Nature Reviews. Cancer 10 332-341. (doi:10.1038/nrc2775)
80. Iwai K & Tokunaga F 2009 Linear polyubiquitination: a new regulator of NF-κB activation. EMBO Reports 10 706-713. (doi:10.1038/embor.2009.144)
81. Jager W, Santag S, Weidner-Glunde M, Gellermann E, Kati S, Pietrek M, Viejo-Borbolla A & Schulz TF 2012 The ubiquitin-specific protease USP modulates the replication of Kaposi's sarcoma-associated herpesvirus latent episomal DNA. Journal of Virology 86 6745-6757. (doi:10.1128/JVI.06840-11)
82. Jensen DE, Proctor M, Marquis ST, Gardner HP, Ha SI, Chodosh LA, Ishov AM, Tommerup N, Vissing H, Sekido Y et al. 1998 BAP1: a nove ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression. Oncogene 16 1097-1112. (doi:10.1038/sj.onc.1201861)
83. Ji Z, Mohammed H, Webber A, Ridsdale J, Han N, Carroll JS & Sharrocks AD 2014 The forkhead transcription factor FOXK2 acts as a chromatin targeting factor for the BAP1-containing histone deubiquitinase complex. Nucleic Acids Research 42 6232-6242. (doi:10.1093/nar/gku274)
84. Jin C, Yu W, Lou X, Zhou F, Han X, Zhao N & Lin B 2013 UCHL1 is a putative tumor suppressor in ovarian cancer cells and contributes to cisplatin resistance. Journal of Cancer 4 662-670. (doi:10.7150/jca.6641
85. Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, Xie M, Zhang Q, McMichael JF, Wyczalkowski MA et al. 2013 Mutational landscape and significance across 12 major cancer types. Nature 502 333-339. (doi:10.1038/nature12634)
86. Kato N, Yamamoto H, Adachi Y, Ohashi H, Taniguchi H, Suzuki H, Nakazawa M, Kaneto H, Sasaki S, Imai K et al. 2013 Cancer detection b ubiquitin carboxyl-terminal esterase L1 methylation in pancreatobiliary fluids. World Journal of Gastroenterology 19 1718-1727. (doi:10.3748/wjg.v19.i11.1718)
87. Khoronenkova SV & Dianov GL 2013 USP7S-dependent inactivation of Mule regulates DNA damage signalling and repair. Nucleic Acids Research 41 1750-1756. (doi:10.1093/nar/gks1359)
88. Kim JH, Park KC, Chung SS, Bang O & Chung CH 2003 Deubiquitinating enzymes as cellular regulators. Journal of Biochemistry 134 9-18. (doi:10.1093/jb/mvg107)
89. van der Knaap JA, Kumar BR, Moshkin YM, Langenberg K, Krijgsveld J, Heck AJ, Karch F & Verrijzer CP 2005 GMP synthetase stimulates histone H2B deubiquitylation by the epigenetic silencer USP7. Molecular Cell 17 695-707. (doi:10.1016/j.molcel.2005.02.013)
90. van der Knaap JA, Kozhevnikova E, Langenberg K, Moshkin YM & Verrijzer CP 2009 Biosynthetic enzyme GMP synthetase cooperates with ubiquitin-specific protease 7 in transcriptional regulation of ecdysteroid target genes. Molecular and Cellular Biology 30 736-744. (doi:10.1128/MCB.01121-09)
91. Köhler A, Zimmerman E, Schneider M, Hurt E & Zheng N 2010 Structural basis for assembly and activation of the heterotetrameric SAGA histone H2B deubiquitinase module. Cell 141 606-617. (doi:10.1016/j.cell.2010.04.026)
92. Komander D 2009 The emerging complexity of protein ubiquitination. Biochemical Society Transactions 37 937-953. (doi:10.1042/BST0370937)
93. Komander D & Barford D 2008 Structure of the A20 OTU domain and mechanistic insights into deubiquitination. Biochemical Journal 409 77-85. (doi:10.1042/BJ20071399)
94. Komander D, Lord CJ, Scheel H, Swift S, Hofmann K, Ashworth A & Barford D 2008 The structure of the CYLD USP domain explains its specificity for Lys63-linked polyubiquitin and reveals a B box module. Molecular Cell 29 451-464. (doi:10.1016/j.molcel.2007.12.018)
95. Kon N, Kobayashi Y, Li M, Brooks CL, Ludwig T & Gu W 2010 Inactivation of HAUSP in vivo modulates p53 function. Oncogene 29 1270-1279. (doi:10.1038/onc.2009.427)
96. Kovalenko A, Chable-Bessia C, Cantarella G, Israel A, Wallach D & Courtois G 2003 The tumour suppressor CYLD negatively regulates NF-κB signalling by deubiquitination. Nature 424 801-805. (doi:10.1038/nature01802)
97. Krikos A, Laherty CD & Dixit VM 1992 Transcriptional activation of the tumor necrosis factor alpha-inducible zinc finger protein, A20, is mediated by κB elements. Journal of Biological Chemistry 267 17971-17976.
98. Kulathu Y, Garcia FJ, Mevissen TE, Busch M, Arnaudo N, Carroll KS, Barford D & Komander D 2013 Regulation of A20 and other OTU deubiquitinases by reversible oxidation. Nature Communications 4 1569. (doi:10.1038/ncomms2567)
99. Lander GC, Estrin E, Matyskiela ME, Bashore C, Nogales E & Martin A 2012 Complete subunit architecture of the proteasome regulatory particle. Nature 482 186-191. (doi:10.1038/nature10774)
100. Larsen CN, Krantz BA & Wilkinson KD 1998 Substrate specificity of deubiquitinating enzymes: ubiquitin C-terminal hydrolases. Biochemistry 37 3358-3368. (doi:10.1021/bi972274d)
101. Laurell C, Velazquez-Fernandez D, Lindsten K, Juhlin C, Enberg U, Geli J, Hoog A, Kjellman M, Lundeberg J, Hamberger B et al. 2009 Transcriptional profiling enables molecular classification of adreno-cortical tumours. European Journal of Endocrinology 161 141-152. (doi:10.1530/EJE-09-0068)
102. Lee HR, Choi WC, Lee S, Hwang J, Hwang E, Guchhait K, Haas J, Toth Z, Jeon YH, Oh TK et al. 2011 Bilateral inhibition of HAUSP deubiquitinase by a viral interferon regulatory factor protein. Nature Structural & Molecular Biology 18 1336-1344. (doi:10.1038/nsmb.2142)
103. Leiblich A, Cross SS, Catto JW, Pesce G, Hamdy FC & Rehman I 2007 Human prostate cancer cells express neuroendocrine cell markers PGP 9.5 and chromogranin A. Prostate 67 1761-1769. (doi:10.1002/pros. 20654)
104. Leroy E, Boyer R, Auburger G, Leube B, Ulm G, Mezey E, Harta G, Brownstein MJ, Jonnalagada S, Chernova T et al. 1998 The ubiquitin pathway in Parkinson's disease. Nature 395 451-452. (doi:10.1038/26652)
105. Li M, Chen D, Shiloh A, Luo J, Nikolaev AY, Qin J & Gu W 2002a Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization. Nature 416 648-653. (doi:10.1038/nature737)
106. Li Z, Wang D, Na X, Schoen SR, Messing EM & Wu G 2002b Identification of a deubiquitinating enzyme subfamily as substrates of the von Hippel-Lindau tumor suppressor. Biochemical and Biophysical Research Communications 294 700-709. (doi:10.1016/S0006-291X(02)00534-X)
107. Li Z, Na X, Wang D, Schoen SR, Messing EM & Wu G 2002c Ubiquitination of a novel deubiquitinating enzyme requires direct binding to von Hippel-Lindau tumor suppressor protein. Journal of Biological Chemistry 277 4656-4662. (doi:10.1074/jbc.M108269200)
108. Li Z, Wang D, Messing EM & Wu G 2005 VHL protein-interacting deubiquitinating enzyme 2 deubiquitinates and stabilizes HIF-1a. EMBO Reports 6 373-378. (doi:10.1038/sj.embor.7400377)
109. Li J, Olson LM, Zhang Z, Li L, Bidder M, Nguyen L, Pfeifer J & Rader JS 2008 Differential display identifies overexpression of the USP36 gene, encoding a deubiquitinating enzyme, in ovarian cancer. International Journal of Medical Sciences 5 133-142. (doi:10.7150/ijms.5.133)
110. Li L, Wen S, Wang B, Gao W, Zhang W, Meng X, Yang L & Kong L 2014 [Expression of cancer stem cell marker USP22 in laryngeal squamous cell carcinoma]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 49 479-482.
111. Lin SC, Chung JY, Lamothe B, Rajashankar K, Lu M, Lo YC, Lam AY, Darnay BG & Wu H 2008 Molecular basis for the unique deubiquitinating activity of the NF-κB inhibitor A20. Journal of Molecular Biology 376 526-540. (doi:10.1016/j.jmb.2007.11.092)
112. Lin Z, Yang H, Kong Q, Li J, Lee SM, Gao B, Dong H, Wei J, Song J, Zhang DD et al. 2012 USP22 antagonizes p53 transcriptional activation by deubiquitinating Sirt1 to suppress cell apoptosis and is required for mouse embryonic development. Molecular Cell 46 484-494. (doi:10.1016/j.molcel.2012.03.024)
113. Liu Y, Fallon L, Lashuel HA, Liu Z & Lansbury PT Jr 2002 The UCH-L1 gene encodes two opposing enzymatic activities that affect α-synuclein degradation and Parkinson's disease susceptibility. Cell 111 209-218. (doi:10.1016/S0092-8674(02)01012-7)
114. Liu Y, Yang Y, Xu H & Dong X 2010 Implication of USP22 in the regulation of BMI-1, c-Myc, p16INK4a, p14ARF, and cyclin D2 expression in primary colorectal carcinomas. Diagnostic Molecular Pathology 19 194-200. (doi:10.1097/PDM.0b013e3181e202f2)
115. Liu L, Zhao Q, Liang X, Du G, Lu L, Dong J & Han H 2014 [Expression of neuronal marker protein gene product 9.5 and its clinicopathologic significance in breast cancer]. Zhonghua Bing Li Xue Za Zhi 43 318-320.
116. Lu Y, Bedard N, Chevalier S & Wing SS 2011 Identification of distinctive patterns of USP19-mediated growth regulation in normal and malignant cells. PLoS ONE 6 e15936. (doi:10.1371/journal.pone. 0015936)
117. Lu H, Wang X, Urvalek AM, Li T, Xie H, Yu L & Zhao J 2014 Transformation of human ovarian surface epithelial cells by Kruppel-like factor 8. Oncogene 33 10-18. (doi:10.1038/onc.2012.545)
118. Luise C, Capra M, Donzelli M, Mazzarol G, Jodice MG, Nuciforo P, Viale G, Di Fiore PP & Confalonieri S 2011 An atlas of altered expression of deubiquitinating enzymes in human cancer. PLoS ONE 6 e15891. (doi:10.1371/journal.pone.0015891)
119. Ma Z, Gao X, Zhao W, Li Y & Li C 2009 Relationship between expression of Pad1 homologue and multidrug resistance of idiopathic nephrotic syndrome. Pediatrics International 51 732-735. (doi:10.1111/j.1442-200X.2009.02845.x)
120. Machida YJ, Machida Y, Vashisht AA, Wohlschlegel JA & Dutta A 2009 The deubiquitinating enzyme BAP1 regulates cell growth via interaction with HCF-1. Journal of Biological Chemistry 284 34179-34188. (doi:10.1074/jbc.M109.046755)
121. Maertens GN, El Messaoudi-Aubert S, Elderkin S, Hiom K & Peters G 2010 Ubiquitin-specific proteases 7 and 11 modulate polycomb regulation of the INK4a tumour suppressor. EMBO Journal 29 2553-2565. (doi:10.1038/emboj.2010.129)
122. Mao Y, Senic-Matuglia F, Di Fiore PP, Polo S, Hodsdon ME & De Camilli P 2005 Deubiquitinating function of ataxin-3: insights from the solution structure of the Josephin domain. PNAS 102 12700-12705. (doi:10.1073/pnas.0506344102)
123. Massoumi R 2011 CYLD: a deubiquitination enzyme with multiple roles in cancer. Future Oncology 7 285-297. (doi:10.2217/fon.10.187)
124. Masuya D, Huang C, Liu D, Nakashima T, Yokomise H, Ueno M, Nakashima N & Sumitomo S 2006 The HAUSP gene plays an important role in non-small cell lung carcinogenesis through p53-dependent pathways. Journal of Pathology 208 724-732. (doi:10.1002/path.1931)
125. Meredith M, Orr A & Everett R 1994 Herpes simplex virus type 1 immediate-early protein Vmw110 binds strongly and specifically to a 135-kDa cellular protein. Virology 200 457-469. (doi:10.1006/viro.1994.1209)
126. Meulmeester E, Maurice MM, Boutell C, Teunisse AF, Ovaa H, Abraham TE, Dirks RW & Jochemsen AG 2005 Loss of HAUSP-mediated deubiquitination contributes to DNA damage-induced destabilization of Hdmx and Hdm2. Molecular Cell 18 565-576. (doi:10.1016/j.molcel.2005.04.024)
127. Miranda M & Sorkin A 2007 Regulation of receptors and transporters by ubiquitination: new insights into surprisingly similar mechanisms. Molecular Interventions 7 157-167. (doi:10.1124/mi.7.3.7)
128. Misaghi S, Ottosen S, Izrael-Tomasevic A, Arnott D, Lamkanfi M, Lee J, Liu J, O'Rourke K, Dixit VM & Wilson AC 2009 Association of C-terminal ubiquitin hydrolase BRCA1-associated protein 1 with cell cycle regulator host cell factor 1. Molecular and Cellular Biology 29 2181-2192. (doi:10.1128/MCB.01517-08)
129. Morotti A, Panuzzo C, Crivellaro S, Pergolizzi B, Familiari U, Berger AH, Saglio G & Pandolfi PP 2014 BCR-ABL disrupts PTEN nuclear-cytoplasmic shuttling through phosphorylation-dependent activation of HAUSP. Leukemia 28 1326-1333. (doi:10.1038/leu.2013.370)
130. Mosbech A, Lukas C, Bekker-Jensen S & Mailand N 2013 The deubiquity-lating enzyme USP44 counteracts the DNA double-strand break response mediated by the RNF8 and RNF168 ubiquitin ligases. Journal of Biological Chemistry 288 16579-16587. (doi:10.1074/jbc.M113.459917)
131. Nanao MH, Tcherniuk SO, Chroboczek J, Dideberg O, Dessen A & Balakirev MY 2004 Crystal structure of human otubain 2. EMBO Reports 5 783-788. (doi:10.1038/sj.embor.7400201)
132. Nicastro G, Menon RP, Masino L, Knowles PP, McDonald NQ & Pastore A 2005 The solution structure of the Josephin domain of ataxin-3: structural determinants for molecular recognition. PNAS 102 10493-10498. (doi:10.1073/pnas.0501732102)
133. Nijman SM, Luna-Vargas MP, Velds A, Brummelkamp TR, Dirac AM, Sixma TK & Bernards R 2005 A genomic and functional inventory of deubiquitinating enzymes. Cell 123 773-786. (doi:10.1016/j.cell.2005.11.007)
134. Okochi-Takada E, Nakazawa K, Wakabayashi M, Mori A, Ichimura S, Yasugi T & Ushijima T 2006 Silencing of the UCHL1 gene in human colorectal and ovarian cancers. International Journal of Cancer. Journal International du Cancer 119 1338-1344. (doi:10.1002/ijc.22025)
135. Pal A, Young MA & Donato NJ 2014 Emerging potential of therapeutic targeting of ubiquitin-specific proteases in the treatment of cancer. Cancer Research 74 4955-4966. (doi:10.1158/0008-5472.CAN-14-1211)
136. Panier S & Durocher D 2009 Regulatory ubiquitylation in response to DNA double-strand breaks. DNA Repair 8 436-443. (doi:10.1016/j.dnarep.2009.01.013)
137. Parviainen H, Schrade A, Kiiveri S, Prunskaite-Hyyrylainen R, Haglund C, Vainio S, Wilson DB, Arola J & Heikinheimo M 2013 Expression of Wnt and TGF-β pathway components and key adrenal transcription factors in adrenocortical tumors: association to carcinoma aggressiveness. Pathology, Research and Practice 209 503-509. (doi:10.1016/j.prp.2013.06.002)
138. Pathare GR, Nagy I, Sledz P, Anderson DJ, Zhou HJ, Pardon E, Steyaert J, Forster F, Bracher A & Baumeister W 2014 Crystal structure of the proteasomal deubiquitylation module Rpn8-Rpn11. PNAS 111 2984-2989. (doi:10.1073/pnas.1400546111)
139. Piao S, Liu Y, Hu J, Guo F, Ma J, Sun Y & Zhang B 2012 USP22 is useful as a novel molecular marker for predicting disease progression and patient prognosis of oral squamous cell carcinoma. PLoS ONE 7 e42540. (doi:10.1371/journal.pone.0042540)
140. Piao S, Ma J, Wang W, Liu Y, Zhang M, Chen H, Guo F & Zhang B 2013 Increased expression of USP22 is associated with disease progression and patient prognosis of salivary duct carcinoma. Oral Oncology 49 796-801. (doi:10.1016/j.oraloncology.2013.03.454)
141. Pickart CM 2001 Mechanisms underlying ubiquitination. Annual Review of Biochemistry 70 503-533. (doi:10.1146/annurev.biochem.70.1.503)
142. Planchon SM, Waite KA & Eng C 2008 The nuclear affairs of PTEN. Journal of Cell Science 121 249-253. (doi:10.1242/jcs.022459)
143. Priolo C, Tang D, Brahamandan M, Benassi B, Sicinska E, Ogino S, Farsetti A, Porrello A, Finn S, Zimmermann J et al. 2006 The isopeptidase USP2a protects human prostate cancer from apoptosis. Cancer Research 66 8625-8632. (doi:10.1158/0008-5472.CAN-06-1374)
144. Reddy BA, van der Knaap JA, Bot AG, Mohd-Sarip A, Dekkers DH, Timmermans MA, Martens JW, Demmers JA & Verrijzer CP 2014 Nucleotide biosynthetic enzyme GMP synthase is a TRIM21-controlled relay of p53 stabilization. Molecular Cell 53 458-470. (doi:10.1016/j.molcel.2013.12.017)
145. Reiner T, Parrondo R, de Las Pozas A, Palenzuela D & Perez-Stable C 2013 Betulinic acid selectively increases protein degradation and enhances prostate cancer-specific apoptosis: possible role for inhibition of deubiquitinase activity. PLoS ONE 8 e56234. (doi:10.1371/journal. pone.0056234)
146. Renatus M, Parrado SG, D'Arcy A, Eidhoff U, Gerhartz B, Hassiepen U, Pierrat B, Riedl R, Vinzenz D, Worpenberg S et al. 2006 Structural basis of ubiquitin recognition by the deubiquitinating protease USP2. Structure 14 1293-1302. (doi:10.1016/j.str.2006.06.012)
147. Reverdy C, Conrath S, Lopez R, Planquette C, Atmanene C, Collura V, Harpon J, Battaglia V, Vivat V, Sippl W et al. 2012 Discovery of specific inhibitors of human USP7/HAUSP deubiquitinating enzyme. Chemistry & Biology 19 467-477. (doi:10.1016/j.chembiol.2012.02.007)
148. Reyes-Turcu FE & Wilkinson KD 2009 Polyubiquitin binding and disassembly by deubiquitinating enzymes. Chemical Reviews 109 1495-1508. (doi:10.1021/cr800470j)
149. Rode J, Dhillon AP, Doran JF, Jackson P & Thompson RJ 1985 PGP 9.5, a new marker for human neuroendocrine tumours. Histopathology 9 147-158. (doi:10.1111/j.1365-2559.1985.tb02431.x)
150. Sacco JJ, Yau TY, Darling S, Patel V, Liu H, Urbe S, Clague MJ & Coulson JM 2014 The deubiquitylase ataxin-3 restricts PTEN transcription in lung cancer cells. Oncogene 33 4265-4272. (doi:10.1038/onc.2013.512)
151. Saito K, Kigawa T, Koshiba S, Sato K, Matsuo Y, Sakamoto A, Takagi T, Shirouzu M, Yabuki T, Nunokawa E et al. 2004 The CAP-Gly domain of CYLD associates with the proline-rich sequence in NEMO/IKKγ. Structure 12 1719-1728. (doi:10.1016/j.str.2004.07.012)
152. Salsman J, Jagannathan M, Paladino P, Chan PK, Dellaire G, Raught B & Frappier L 2012 Proteomic profiling of the human cytomegalovirus UL35 gene products reveals a role for UL35 in the DNA repair response. Journal of Virology 86 806-820. (doi:10.1128/JVI.05442-11)
153. Samara NL, Datta AB, Berndsen CE, Zhang X, Yao T, Cohen RE & Wolberger C 2010 Structural insights into the assembly and function of the SAGA deubiquitinating module. Science 328 1025-1029. (doi:10.1126/science.1190049)
154. Samara NL, Ringel AE & Wolberger C 2012 A role for intersubunit interactions in maintaining SAGA deubiquitinating module structure and activity. Structure 20 1414-1424. (doi:10.1016/j.str.2012.05.015)
155. Saridakis V, Sheng Y, Sarkari F, Holowaty MN, Shire K, Nguyen T, Zhang RG, Liao J, Lee W, Edwards AM et al. 2005 Structure of the p53 binding domain of HAUSP/USP7 bound to Epstein-Barr nuclear antigen 1 implications for EBV-mediated immortalization. Molecular Cell 18 25-36. (doi:10.1016/j.molcel.2005.02.029)
156. Sarkari F, Sanchez-Alcaraz T, Wang S, Holowaty MN, Sheng Y & Frappier L 2009 EBNA1-mediated recruitment of a histone H2B deubiquitylating complex to the Epstein-Barr virus latent origin of DNA replication. PLoS Pathogens 5 e1000624. (doi:10.1371/journal.ppat.1000624)
157. Sarkari F, La Delfa A, Arrowsmith CH, Frappier L, Sheng Y & Saridakis V 2010 Further insight into substrate recognition by USP7: structural and biochemical analysis of the HdmX and Hdm2 interactions with USP7. Journal of Molecular Biology 402 825-837. (doi:10.1016/j.jmb.2010.08.017)
158. Sarkari F, Wheaton K, La Delfa A, Mohamed M, Shaikh F, Khatun R, Arrowsmith CH, Frappier L, Saridakis V & Sheng Y 2013 Ubiquitin-specific protease 7 is a regulator of ubiquitin-conjugating enzyme UbE2E1. Journal of Biological Chemistry 288 16975-16985. (doi:10.1074/jbc.M113.469262)
159. Sato Y, Yoshikawa A, Yamagata A, Mimura H, Yamashita M, Ookata K, Nureki O, Iwai K, Komada M & Fukai S 2008 Structural basis for specific cleavage of Lys 63-linked polyubiquitin chains. Nature 455 358-362. (doi:10.1038/nature07254)
160. Scaglione KM, Zavodszky E, Todi SV, Patury S, Xu P, Rodriguez-Lebron E, Fischer S, Konen J, Djarmati A, Peng J et al. 2011 Ube2w and ataxin-3 coordinately regulate the ubiquitin ligase CHIP. Molecular Cell 43 599-612. (doi:10.1016/j.molcel.2011.05.036)
161. Scheuermann JC, de Ayala Alonso AG, Oktaba K, Ly-Hartig N, McGinty RK, Fraterman S, Wilm M, Muir TW & Muller J 2010 Histone H2A deubiquitinase activity of the polycomb repressive complex PR-DUB. Nature 465 243-247. (doi:10.1038/nature08966)
162. Schrecengost RS, Dean JL, Goodwin JF, Schiewer MJ, Urban MW, Stanek TJ, Sussman RT, Hicks JL, Birbe RC, Draganova-Tacheva RA et al. 2014 USP22 regulates oncogenic signaling pathways to drive lethal cancer progression. Cancer Research 74 272-286. (doi:10.1158/0008-5472.CAN-13-1954)
163. Schweitzer K, Bozko PM, Dubiel W & Naumann M 2007 CSN controls NF-κB by deubiquitinylation of IκBα. EMBO Journal 26 1532-1541. (doi:10.1038/sj.emboj.7601600)
164. Shanmugam I, Abbas M, Ayoub F, Mirabal S, Bsaili M, Caulder EK, Weinstock DM, Tomkinson AE, Hromas R & Shaheen M 2014 Ubiquitin-specific peptidase 20 regulates Rad17 stability, checkpoint kinase 1 phosphorylation and DNA repair by homologous recombination. Journal of Biological Chemistry 289 22739-22748. (doi:10.1074/jbc.M114.550459)
165. Shembade N, Pujari R, Harhaj NS, Abbott DW & Harhaj EW 2011 The kinase IKKα inhibits activation of the transcription factor NF-κB by phosphorylating the regulatory molecule TAX1BP1. Nature Immunology 12 834-843. (doi:10.1038/ni.2066)
166. Sheng Y, Saridakis V, Sarkari F, Duan S, Wu T, Arrowsmith CH & Frappier L 2006 Molecular recognition of p53 and MDM2 by USP7/HAUSP. Nature Structural & Molecular Biology 13 285-291. (doi:10.1038/nsmb1067)
167. Siegel R, Ma J, Zou Z & Jemal A 2014 Cancer statistics, 2014. CA: A Cancer Journal for Clinicians 64 9-29. (doi:10.3322/caac.21208)
168. Sloane MA, Wong JW, Perera D, Nunez AC, Pimanda JE, Hawkins NJ, Sieber OM, Bourke MJ, Hesson LB & Ward RL 2014 Epigenetic inactivation of the candidate tumor suppressor USP44 is a frequent and early event in colorectal neoplasia. Epigenetics 9 1092-1100. (doi:10.4161/epi.29222)
169. Smit JJ & Sixma TK 2014 RBR E3-ligases at work. EMBO Reports 15 142-154. (doi:10.1002/embr.201338166)
170. Song MS, Salmena L, Carracedo A, Egia A, Lo-Coco F, Teruya-Feldstein J & Pandolfi PP 2008 The deubiquitinylation and localization of PTEN are regulated by a HAUSP-PML network. Nature 455 813-817. (doi:10.1038/nature07290)
171. Spataro V, Simmen K & Realini CA 2002 The essential 26S proteasome subunit Rpn11 confers multidrug resistance to mammalian cells. Anticancer Research 22 3905-3909.
172. Spratt DE, Walden H & Shaw GS 2014 RBR E3 ubiquitin ligases: new structures, new insights, new questions. Biochemical Journal 458 421-437. (doi:10.1042/BJ20140006)
173. Stanley JA, Aruldhas MM, Chandrasekaran M, Neelamohan R, Suthagar E, Annapoorna K, Sharmila S, Jayakumar J, Jayaraman G, Srinivasan N et al. 2012 Androgen receptor expression in human thyroid cancer tissues: a potential mechanism underlying the gender bias in the incidence of thyroid cancers. Journal of Steroid Biochemistry and Molecular Biology 130 105-124. (doi:10.1016/j.jsbmb.2012.02.004)
174. Steele JM 2013 Carfilzomib: a new proteasome inhibitor for relapsed or refractory multiple myeloma. Journal of Oncology Pharmacy Practice 19 348-354. (doi:10.1177/1078155212470388)
175. Stevenson LF, Sparks A, Allende-Vega N, Xirodimas DP, Lane DP & Saville MK 2007 The deubiquitinating enzyme USP2a regulates the p53 pathway by targeting Mdm2. EMBO Journal 26 976-986. (doi:10.1038/sj.emboj.7601567)
176. Sun T, Lee GS, Oh WK, Pomerantz M, Yang M, Xie W, Freedman ML & Kantoff PW 2010 Single-nucleotide polymorphisms in p53 pathway and aggressiveness of prostate cancer in a Caucasian population. Clinical Cancer Research 16 5244-5251. (doi:10.1158/1078-0432.CCR-10-1261)
177. Takano T, Miyauchi A, Matsuzuka F, Yoshida H, Nakata Y, Kuma K & Amino N 2004 PGP9.5 mRNA could contribute to the molecular-based diagnosis of medullary thyroid carcinoma. European Journal of Cancer 40 614-618. (doi:10.1016/j.ejca.2003.11.016)
178. Terzic J, Marinovic-Terzic I, Ikeda F & Dikic I 2007 Ubiquitin signals in the NF-κB pathway. Biochemical Society Transactions 35 942-945. (doi:10.1042/BST0350942)
179. Tezel E, Hibi K, Nagasaka T & Nakao A 2000 PGP9.5 as a prognostic factor in pancreatic cancer. Clinical Cancer Research 6 4764-4767.
180. Thompson RJ, Doran JF, Jackson P, Dhillon AP & Rode J 1983 PGP9.5 - a new marker for vertebrate neurons and neuroendocrine cells. Brain Research 278 224-228. (doi:10.1016/0006-8993(83)90241-X)
181. Tokunaga F, Nishimasu H, Ishitani R, Goto E, Noguchi T, Mio K, Kamei K, Ma A, Iwai K & Nureki O 2012 Specific recognition of linear polyubiquitin by A20 zinc finger 7 is involved in NF-κB regulation. EMBO Journal 31 3856-3870. (doi:10.1038/emboj.2012.241)
182. Tomita T 2013 PGP 9.5 immunocytochemical staining for pancreatic endocrine tumors. Islets 5 122-128. (doi:10.4161/isl.25351)
183. Tootee A & Hasani-Ranjbar S 2012 Von Hippel-Lindau disease: a new approach to an old problem. International Journal of Endocrinology and Metabolism 10 619-624. (doi:10.5812/ijem.4510)
184. Trompouki E, Hatzivassiliou E, Tsichritzis T, Farmer H, Ashworth A & Mosialos G 2003 CYLD is a deubiquitinating enzyme that negatively regulates NF-κB activation by TNFR family members. Nature 424 793-796. (doi:10.1038/nature01803)
185. Tsirlin A, Oo Y, Sharma R, Kansara A, Gliwa A & Banerji MA 2014 Pheochromocytoma: a review. Maturitas 77 229-238. (doi:10.1016/j.maturitas.2013.12.009)
186. Ummanni R, Jost E, Braig M, Lohmann F, Mundt F, Barett C, Schlomm T, Sauter G, Senff T, Bokemeyer C et al. 2011 Ubiquitin carboxyl-terminal hydrolase 1 (UCHL1) is a potential tumour suppressor in prostate cancer and is frequently silenced by promoter methylation. Molecular Cancer 10 129. (doi:10.1186/1476-4598-10-129)
187. Uras IZ, List T & Nijman SM 2012 Ubiquitin-specific protease 4 inhibits mono-ubiquitination of the master growth factor signaling kinase PDK1. PLoS ONE 7 e31003. (doi:10.1371/journal.pone.0031003)
188. Velazquez-Fernandez D, Laurell C, Geli J, Hoog A, Odeberg J, Kjellman M, Lundeberg J, Hamberger B, Nilsson P & Backdahl M 2005 Expression profiling of adrenocortical neoplasms suggests a molecular signature of malignancy. Surgery 138 1087-1094. (doi:10.1016/j.surg.2005.09.031)
189. Vendrell JA, Ghayad S, Ben-Larbi S, Dumontet C, Mechti N & Cohen PA 2007 A20/TNFAIP3, a new estrogen-regulated gene that confers tamoxifen resistance in breast cancer cells. Oncogene 26 4656-4667. (doi:10.1038/sj.onc.1210269)
190. Ventii KH, Devi NS, Friedrich KL, Chernova TA, Tighiouart M, Van Meir EG & Wilkinson KD 2008 BRCA1-associated protein-1 is a tumor suppressor that requires deubiquitinating activity and nuclear localization. Cancer Research 68 6953-6962. (doi:10.1158/0008-5472.CAN-08-0365)
191. Verstrepen L, Verhelst K, Carpentier I& Beyaert R 2011 TAX1BP1, a ubiquitin-binding adaptor protein in innate immunity and beyond. Trends in Biochemical Sciences 36 347-354. (doi:10.1016/j.tibs.2011.03.004)
192. Wang YZ & Wong YC 1997 Oncogenes and tumor suppressor genes in prostate cancer: a review. Urologic Oncology 3 41-46. (doi:10.1016/S1078-1439(97)00021-5)
193. Wang G, Gao Y, Li L, Jin G, Cai Z, Chao JI & Lin HK 2012 K63-linked ubiquitination in kinase activation and cancer. Frontiers in Oncology 2 5. (doi:10.3389/fonc.2012.00005)
194. Wang H, Li YP, Chen JH, Yuan SF, Wang L, Zhang JL, Yao Q, Li NL, Bian JF, Fan J et al. 2013 Prognostic significance of USP22 as an oncogene in papillary thyroid carcinoma. Tumour Biology 34 1635-1639. (doi:10.1007/s13277-013-0696-0)
195. Wang L, Chen YJ, Xu K, Wang YY, Shen XZ & Tu RQ 2014 High expression of UCH37 is significantly associated with poor prognosis in human epithelial ovarian cancer. Tumour Biology 35 11427-11433. (doi:10.1007/s13277-014-2446-3)
196. Warrick JM, Morabito LM, Bilen J, Gordesky-Gold B, Faust LZ, Paulson HL & Bonini NM 2005 Ataxin-3 suppresses polyglutamine neurodegeneration in Drosophila by a ubiquitin-associated mechanism. Molecular Cell 18 37-48. (doi:10.1016/j.molcel.2005.02.030)
197. Weinstock J, Wu J, Cao P, Kingsbury WD, McDermott JL, Kodrasov MP, McKelvey DM, Suresh Kumar KG, Goldenberg SJ, Mattern MR et al. 2012 Selective dual inhibitors of the cancer-related deubiquitylating proteases USP7 and USP47. ACS Medicinal Chemistry Letters 3 789-792. (doi:10.1021/ml200276j)
198. Weissman AM 2001 Themes and variations on ubiquitylation. Nature Reviews. Molecular Cell Biology 2 169-178. (doi:10.1038/35056563)
199. Wen D, Xu Z, Xia L, Liu X, Tu Y, Lei H, Wang W, Wang T, Song L, Ma C et al. 2014 Important role of SUMOylation of Spliceosome factors in prostate cancer cells. Journal of Proteome Research 13 3571-3582. (doi:10.1021/pr4012848)
200. Wertz IE, O'Rourke KM, Zhou H, Eby M, Aravind L, Seshagiri S, Wu P, Wiesmann C, Baker R, Boone DL et al. 2004 De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-κB signalling. Nature 430 694-699. (doi:10.1038/nature02794)
201. Wosnitzer MS, Mielnik A, Dabaja A, Robinson B, Schlegel PN & Paduch DA 2014 Ubiquitin specific protease 26 (USP26) expression analysis in human testicular and extragonadal tissues indicates diverse action of USP26 in cell differentiation and tumorigenesis. PLoS ONE 9 e98638. (doi:10.1371/journal.pone.0098638)
202. Xiang T, Li L, Yin X, Yuan C, Tan C, Su X, Xiong L, Putti TC, Oberst M, Kelly K et al. 2012 The ubiquitin peptidase UCHL1 induces G0/G1 cell cycle arrest and apoptosis through stabilizing p53 and is frequently silenced in breast cancer. PLoS ONE 7 e29783. (doi:10.1371/journal. pone.0029783)
203. Xu M, Takanashi M, Oikawa K, Tanaka M, Nishi H, Isaka K, Kudo M & Kuroda M 2009 USP15 plays an essential role for caspase-3 activation during paclitaxel-induced apoptosis. Biochemical and Biophysical Research Communications 388 366-371. (doi:10.1016/j.bbrc.2009.08.015)
204. Xue S & Jia J 2006 Genetic association between ubiquitin carboxy-terminal hydrolase-L1 gene S18Y polymorphism and sporadic Alzheimer's disease in a Chinese Han population. Brain Research 1087 28-32. (doi:10.1016/j.brainres.2006.02.121)
205. Yamaguchi M, Miyazaki M, Kodrasov MP, Rotinsulu H, Losung F, Mangindaan RE, de Voogd NJ, Yokosawa H, Nicholson B & Tsukamoto S 2013 Spongiacidin C, a pyrrole alkaloid from the marine sponge Stylissa massa, functions as a USP7 inhibitor. Bioorganic & Medicinal Chemistry Letters 23 3884-3886. (doi:10.1016/j.bmcl.2013.04.066)
206. Yamamoto N, Imai J, Watanabe M, Hiroi N, Sugano S & Yoshino G 2006 Restoration of transforming growth factor-β type II receptor reduces tumorigenicityinthe human adrenocortical carcinoma SW-13 cell line. Hormone and Metabolic Research 38 159-166. (doi:10.1055/s-2006-925185)
207. Yamazaki T, Hibi K, Takase T, Tezel E, Nakayama H, Kasai Y, Ito K, Akiyama S, Nagasaka T & Nakao A 2002 PGP9.5 as a marker for invasive colorectal cancer. Clinical Cancer Research 8 192-195.
208. Yang YA & Yu J 2013 EZH2, an epigenetic driver of prostate cancer. Protein & Cell 4 331-341. (doi:10.1007/s13238-013-2093-2)
209. Yang Y, Hou JQ, Qu LY, Wang GQ, JuHW, Zhao ZW, Yu ZH & Yang HJ 2007 [Differential expression of USP2, USP14 and UBE4A between ovarian serous cystadenocarcinoma and adjacent normal tissues]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 23 504-506.
210. Yang M, Liu YD, Wang YY, Liu TB, Ge TT & Lou G 2014 Ubiquitin-specific protease 22: a novel molecular biomarker in cervical cancer prognosis and therapeutics. Tumour Biology 35 929-934. (doi:10.1007/s13277-013-1121-4)
211. Yao T & Cohen RE 2002 A cryptic protease couples deubiquitination and degradation by the proteasome. Nature 419 403-407. (doi:10.1038/nature01071)
212. Zarrizi R, Menard J, Belting M & Massoumi R 2014 Deubiquitination of γ-tubulin by BAP1 prevents chromosome instability in breast cancer cells. Cancer Research 74 6499-6508. (doi:10.1158/0008-5472.CAN-14-0221)
213. Zavacki AM, Arrojo EDR, Freitas BC, Chung M, Harney JW, Egri P, Wittmann G, Fekete C, Gereben B & Bianco AC 2009 The E3 ubiquitin ligase TEB4 mediates degradation of type 2 iodothyronine deiodinase. Molecular and Cellular Biology 29 5339-5347. (doi:10.1128/MCB.01498-08)
214. Zhang Y, Yao L, Zhang X, Ji H, Wang L, Sun S & Pang D 2011a Elevated expression of USP22 in correlation with poor prognosis in patients with invasive breast cancer. Journal of Cancer Research and Clinical Oncology 137 1245-1253. (doi:10.1007/s00432-011-0998-9)
215. Zhang X, Berger FG, Yang J & Lu X 2011b USP4 inhibits p53 through deubiquitinating and stabilizing ARF-BP1. EMBO Journal 30 2177-2189. (doi:10.1038/emboj.2011.125)
216. Zhang L, Zhou F, Drabsch Y, Gao R, Snaar-Jagalska BE, Mickanin C, Huang H, Sheppard KA, Porter JA, Lu CX et al. 2012 USP4 is regulated by AKT phosphorylation and directly deubiquitylates TGF-β type I receptor. Nature Cell Biology 14 717-726. (doi:10.1038/ncb2522)
217. Zhang J, Cao M, Dong J, Li C, Xu W, Zhan Y, Wang X, Yu M, Ge C, Ge Z et al. 2014 ABRO1 suppresses tumourigenesis and regulates the DNA damage response by stabilizing p53. Nature Communications 5 5059. (doi:10.1038/ncomms6059)
218. Zhong X & Pittman RN 2006 Ataxin-3 binds VCP/p97 and regulates retrotranslocation of ERAD substrates. Human Molecular Genetics 15 2409-2420. (doi:10.1093/hmg/ddl164)